However, the previous case report by Tran et al. (2016) exhibited an encouraging outcome whereby high effectiveness of antitumor therapy post-adoptive transfer of tumor-infiltrating CD8+ (expanded ex vivo) in a metastatic CRC patient with mutant KRAS G12D expression was demonstrated [125]. This evidence concerns the gene KRAS and neoplasm.